Bull Horn Holdings Corp. (COEPW)

Overview

Coeptis Therapeutics Holdings, Inc. is a pioneering biopharmaceutical enterprise dedicated to developing innovative cell therapy platforms aimed at treating patients suffering from cancer. The company's ambitious efforts are rooted in cutting-edge research and collaboration with leading entities in the biopharmaceutical field. Coeptis Therapeutics is strategically headquartered in Wexford, Pennsylvania, positioning itself in a vibrant hub for pharmaceutical innovation. Through its committed pursuit of excellence in cancer treatment, Coeptis stands at the forefront of harnessing cellular therapies for combating a range of cancerous conditions, thereby offering new hope to patients entrenched in the fight against this formidable disease.

Products and Services

• CD38-GEAR-NK

  This cell therapy is a cornerstone of Coeptis Therapeutics' product lineup, specifically designed to combat CD38-related cancers. It caters to a spectrum of malignant conditions such as multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia. Through targeting the CD38 antigen present on the surface of cancer cells, CD38-GEAR-NK exhibits a promising approach to eradicate cancer cells, illustrating the company's commitment to addressing unmet medical needs in the oncology arena.

• SNAP-CAR

  The SNAP-CAR platform represents a revolutionary advancement in CAR T cell therapy. It is co-administered with tagged, tumor-specific antibodies, offering a versatile and dynamic approach to targeting various tumor types. This includes, but is not limited to, hematological malignancies and solid tumors. SNAP-CAR's innovative design allows for the potential targeting of a broader range of cancerous cells, showcasing Coeptis Therapeutics' dedication to expanding the horizons of cancer treatment.

• CD38-Diagnostic

  As an integral component of Coeptis Therapeutics' arsenal, the CD38-Diagnostic tool serves as an in vitro screening methodology. Its primary function is to ascertain the suitability of cancer patients for anti-CD38 monoclonal antibody (mAb) therapy. This diagnostic tool underscores the company's holistic approach to cancer treatment, not only by providing therapeutic options but also by ensuring the personalized and precise application of such therapies.

On the collaboration front, Coeptis Therapeutics Holdings, Inc. has forged strategic partnerships to broaden its impact within the biopharmaceutical sector. This includes a notable collaboration with Statera BioPharma for the development and commercialization of STAT-201, aimed at treating Crohn's Disease. Additionally, the company has entered into an agreement with Vici Health Sciences, LLC, focusing on the co-development and shared ownership rights of CPT60621, a novel therapeutic initiative for Parkinson's Disease. These collaborations not only exemplify Coeptis' commitment to advancing healthcare but also highlight its strategic approach to leveraging synergies within the industry to tackle a wide array of diseases.